SCHEMBL1613832

SCHEMBL1613832

COC(C)(OC)c1nc(CO)cs1

nearest known ligand 0.32

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HRH1 P35367 1/20 0.32
GUCY1B2 O75343 1/20 0.32
GUCY1A2 P33402 1/20 0.32
GUCY1A1 Q02108 1/20 0.32
GUCY1B1 Q02153 1/20 0.32
KDM4E B2RXH2 3/20 0.31
ALDH1A1 P00352 3/20 0.31
HPGD P15428 2/20 0.31
PTPRB P23467 2/20 0.31
SRC P12931 1/20 0.31
ZAP70 P43403 1/20 0.31
SYK P43405 1/20 0.31
NUDT1 P36639 1/20 0.31
RAB9A P51151 1/20 0.30
TDP1 Q9NUW8 1/20 0.30
PKM P14618 1/20 0.30
GAA P10253 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12714353 0.86 HRH1 (0.32) HRH1GUCY1B2GUCY1A2GUCY1A1GUCY1B1
SCHEMBL10223189 0.81 HRH1 (0.44) HRH1GUCY1B2GUCY1A2GUCY1A1GUCY1B1
SCHEMBL22012330 0.79 SRC (0.34) HRH1GUCY1B2GUCY1A2GUCY1A1GUCY1B1
SCHEMBL8128248 0.79 HRH1 (0.34) HRH1GUCY1B2GUCY1A2GUCY1A1GUCY1B1
SCHEMBL17018481 0.78 HRH1 (0.33) HRH1GUCY1B2GUCY1A2GUCY1A1GUCY1B1
SCHEMBL17018485 0.78 HRH1 (0.33) HRH1GUCY1B2GUCY1A2GUCY1A1GUCY1B1
SCHEMBL19597724 0.76 GUCY1B2 (0.32) GUCY1B2GUCY1A2GUCY1A1GUCY1B1SRC
SCHEMBL16603249 0.76 GUCY1B2 (0.32) GUCY1B2GUCY1A2GUCY1A1GUCY1B1SRC
SCHEMBL10425950 0.75 HRH1 (0.32) HRH1GUCY1B2GUCY1A2GUCY1A1GUCY1B1
SCHEMBL16603243 0.74 F2RL3 (0.35) HRH1GUCY1B2GUCY1A2GUCY1A1GUCY1B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2315751-A1 ALKYNYL ALCOHOLS AS KINASE INHIBITORS Amgen Inc. (US) 2011-05-04 EP disclosed
US-20110086834-A1 ALKYNYL ALCOHOLS AS KINASE INHIBITORS AMGEN INC. (US) 2011-04-14 US disclosed
US-20110086834-A1 ALKYNYL ALCOHOLS AS KINASE INHIBITORS AMGEN INC. (US) 2011-04-14 US disclosed
WO-2009158011-A1 ALKYNYL ALCOHOLS AS KINASE INHIBITORS AMGEN INC. (US) 2009-12-30 WO disclosed
WO-2009158011-A1 ALKYNYL ALCOHOLS AS KINASE INHIBITORS AMGEN INC. (US) 2009-12-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110086834-A1 ALKYNYL ALCOHOLS AS KINASE INHIBITORS NFKBIA, MAP3K1, MAP3K2 HRH1 926/4885GUCY1B2 1469/4885GUCY1A2 1556/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.